Eczema Therapeutics Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Eczema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors), By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The global eczema therapeutics market is projected to grow from USD 14.32 billion in 2025 to USD 22.11 billion by 2031, at a 7.51% CAGR. This market includes topical, oral, and injectable formulations designed to reduce inflammation, relieve itching, and restore skin barrier function in atopic dermatitis patients. Its growth is primarily driven by the increasing global incidence of allergic skin disorders, rapid development of targeted biologic agents and small molecule inhibitors, and elevated diagnostic rates, all of which expand the patient base seeking treatment for chronic skin conditions.
Market Driver
Rapid adoption of novel biologics and JAK inhibitors is a primary market driver, transforming care for moderate-to-severe eczema by offering targeted alternatives to traditional treatments. This is evidenced by Dupixent's Q3 2024 global sales reaching €3,476 million, a 23.8% increase, highlighting strong demand and incentivizing innovation. The rising global prevalence of atopic dermatitis also significantly fuels growth, necessitating diverse therapeutic options for a broadening patient demographic. With approximately 16.5 million adults affected in the U.S. alone, this vast patient pool drives substantial strategic investments and acquisitions, such as Organon's $1.2 billion agreement to acquire Dermavant Sciences in 2024.
Market Challenge
The substantial economic burden of novel therapies presents a critical impediment to market growth. High costs of advanced biologics and small molecule inhibitors create significant access barriers in price-sensitive healthcare systems, leading to restrictive utilization management strategies like step-therapy or high co-pays. This affordability gap forces patients to less effective, lower-cost options, impacting market momentum and treatment adherence. A 2025 survey by the Eczema Society of Canada revealed that 25% of respondents faced financial burden from treatment, leading to reduced prescription fulfillment and hindering commercial expansion.
Market Trends
Innovation in topical formulations prioritizes steroid-free options like PDE4 inhibitors and aryl hydrocarbon receptor agonists to address 'steroid phobia', offering safer long-term management for sensitive areas and pediatric populations. The Zoryve franchise, for example, saw 122% year-over-year revenue increase to $99.2 million by Q3 2025. Concurrently, the market is diversifying from single biologics to multi-agent environments, introducing novel biologics targeting specific pathways like IL-13. This provides alternatives for personalized strategies, fragmenting the biologics share; Almirall's IL-13 inhibitor Ebglyss generated €33.2 million in sales during its initial rollout by February 2025, showing strong demand for new mechanism-driven options.
Key Market Players
* Sanofi SA
* Encore Dermatology Inc.
* AbbVie Inc.
* F Hoffmann-La Roche AG
* Novartis AG
* Regeneron Pharmaceuticals Inc.
* Astellas Pharma Inc.
* GSK PLC
* AstraZeneca PLC
* Pfizer Inc.
Report Scope
In this report, the Global Eczema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Eczema Therapeutics Market, By Treatment
* Antibiotics
* Antihistamines
* Calcineurin Inhibitors
* Corticosteroids
* Emollients & Moisturizers
* Immunomodulators
* Interleukin Inhibitors
# Eczema Therapeutics Market, By Distribution Channel
* Hospital & Clinics
* Online Pharmacies
* Retail Pharmacies
# Eczema Therapeutics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Eczema Therapeutics Market.
Available Customizations:
Global Eczema Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Eczema Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Treatment (Antibiotics, Antihistamines, Calcineurin Inhibitors, Corticosteroids, Emollients & Moisturizers, Immunomodulators, Interleukin Inhibitors)
5.2.2. By Distribution Channel (Hospital & Clinics, Online Pharmacies, Retail Pharmacies)
5.2.3. By Region
5.2.4. By Company (2025)
5.3. Market Map
6. North America Eczema Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Treatment
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Eczema Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Treatment
6.3.1.2.2. By Distribution Channel
6.3.2. Canada Eczema Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Treatment
6.3.2.2.2. By Distribution Channel
6.3.3. Mexico Eczema Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Treatment
6.3.3.2.2. By Distribution Channel
7. Europe Eczema Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Treatment
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Eczema Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Treatment
7.3.1.2.2. By Distribution Channel
7.3.2. France Eczema Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Treatment
7.3.2.2.2. By Distribution Channel
7.3.3. United Kingdom Eczema Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Treatment
7.3.3.2.2. By Distribution Channel
7.3.4. Italy Eczema Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Treatment
7.3.4.2.2. By Distribution Channel
7.3.5. Spain Eczema Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Treatment
7.3.5.2.2. By Distribution Channel
8. Asia Pacific Eczema Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Treatment
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Eczema Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Treatment
8.3.1.2.2. By Distribution Channel
8.3.2. India Eczema Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Treatment
8.3.2.2.2. By Distribution Channel
8.3.3. Japan Eczema Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Treatment
8.3.3.2.2. By Distribution Channel
8.3.4. South Korea Eczema Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Treatment
8.3.4.2.2. By Distribution Channel
8.3.5. Australia Eczema Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Treatment
8.3.5.2.2. By Distribution Channel
9. Middle East & Africa Eczema Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Treatment
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Eczema Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Treatment
9.3.1.2.2. By Distribution Channel
9.3.2. UAE Eczema Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Treatment
9.3.2.2.2. By Distribution Channel
9.3.3. South Africa Eczema Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Treatment
9.3.3.2.2. By Distribution Channel
10. South America Eczema Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Treatment
10.2.2. By Distribution Channel
10.2.3. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Eczema Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Treatment
10.3.1.2.2. By Distribution Channel
10.3.2. Colombia Eczema Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Treatment
10.3.2.2.2. By Distribution Channel
10.3.3. Argentina Eczema Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Treatment
10.3.3.2.2. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Eczema Therapeutics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Sanofi SA
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Encore Dermatology Inc.
15.3. AbbVie Inc.
15.4. F Hoffmann-La Roche AG
15.5. Novartis AG
15.6. Regeneron Pharmaceuticals Inc.
15.7. Astellas Pharma Inc.
15.8. GSK PLC
15.9. AstraZeneca PLC
15.10. Pfizer Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們